Soranix 200mg Tablet 6pcs

✔️ Uses of Soranix 200

Treatment of Cancer (kidney, liver, and thyroid)

✔️ How does Soranix 200 work?

Soranix 200 acts by stopping the action of the abnormal protein that is responsible for the multiplication of cancerous cells. Whenever a new healthy cell is formed it undergoes a usual process of maturity. Cancerous cells form new cells more quickly so Soranix 200 targets cancerous cells and blocks the action of Tyrosine kinase enzymes (responsible for causing cancer). In this way, Soranix 200 Tablet stops the production, spread, and growth of cancerous cells in the body.

✔️ Side Effects: Soranix 200

• Cardiac ischemia, infarction.
• Hypertension.
• Hemorrhage.
• Gastrointestinal perforation.
• Wound healing complications.

✔️ Quick Suggestions:

• Sorafenib is used in the treatment of liver, kidney, and thyroid cancer.
• Take it without food, or with a low-fat meal and a full glass of water.
• Take it at the same time every day to maintain consistent levels in your body.
• Inform your doctor if you get a skin rash, or any pain, swelling, and redness of your hands and feet while you are taking this medicine.
• Do not change the dose or discontinue use without consulting your doctor.
• Take Soranix 200 Tablets exactly as prescribed by the doctor. Do not take in larger or smaller quantities than recommended.
• Take Soranix 200 at least 1 hour before or 2 hours after the meal.
• You may require frequent blood tests and liver function tests while taking this medicine.
• You may also require frequent follow-ups with your doctor to check the progress of treatment.
• Do not stop the use of this medicine without consulting your doctor.
• Women who could get pregnant should use a reliable method of contraception to prevent pregnancy while taking this medicine.
• Your doctor may regularly monitor your blood pressure while you are taking this medicine.

✔️ Pharmacology

• Sorafenib is a kinase inhibitor that blocks multiple intracellular and surface kinases, inhibiting tumor cell proliferation, and angiogenesis, and inducing apoptosis.
• Targets include CRAF, BRAF (and mutant BRAF), KIT, FLT-3, RET, VEGFR-1/2/3, and PDGFR-β.

✔️ Dosage & Administration: Soranix 200

Standard Dose:

• 400 mg tablet, twice daily on an empty stomach (at least 1 hour before or 2 hours after a meal).
• Continue treatment until clinical benefit is lost or unacceptable toxicity occurs.

Dose Adjustments for Toxicity:

• First reduction: 400 mg once daily.
• Second reduction: 400 mg every other day.

Management of Hand-Foot Skin Reaction (HFSR):

• Grade 1: Continue treatment and provide symptomatic relief.
• Grade 2: If no improvement after 7 days or with recurrent events, interrupt treatment and resume at a reduced dose.
• Grade 3: Interrupt treatment until symptoms resolve and resume at a reduced dose. Discontinue after the 3rd recurrence.

• Pediatric Use: Not studied.
• Geriatric Use: No observed differences in efficacy or safety.
• Renal Impairment: No dose adjustment is required.
• Hepatic Impairment:
  • Mild to moderate (Child-Pugh A/B): May reduce Sorafenib plasma concentration by 23–65%.
  • Severe (Child-Pugh C): Not studied.

✔️ Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.

✔️ Missed Dose

Skip the missed dose; take the next dose at the regular time. Do not double the dose.

✔️ Interaction

CYP Enzyme and UGT Substrate Interactions:

• CYP3A4 Inducers (e.g., Rifampin, St. John’s wort): Decrease Sorafenib concentration.
• CYP2B6 and CYP2C8 Substrates: Increased exposure when co-administered.
• UGT1A1 and UGT1A9 Substrates: Increased systemic exposure.

Specific Drug Interactions:

• Docetaxel: Increased AUC (36-80%). Use with caution.
• Doxorubicin: Increased AUC by 21%. Use with caution.
• Fluorouracil: May increase or decrease AUC; monitor closely.
• Neomycin: Reduces Sorafenib exposure by 54%.

✔️ Contraindications:

Soranix 200Contraindicated with Carboplatin and Paclitaxel:

• In squamous cell lung cancer due to increased mortality.

✔️ Pregnancy & Lactation

Based on its mechanism of action and findings in animals, Sorafenib may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant while on Sorafenib. It is not known whether Sorafenib is excreted in human milk.

✔️ Precautions & Warnings

• Risk of ischemia or infarction; consider discontinuation if these occur.
• Increased risk of hemorrhage; discontinue in severe cases.
• Reported in 9.4% (HCC) and 16.9% (RCC) of patients. May require discontinuation if severe.
• Hand-foot skin reactions and rashes are common.
• Discontinue if Gastrointestinal Perforation occurs.
• Resume therapy only after adequate wound healing following major surgery.
• May cause fetal harm. Avoid use during pregnancy and breastfeeding.

✔️ Storage:

• Store at room temperature below 30°C.
• Keep it in the original bottle with the desiccant to protect it from moisture.